These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 15831784)

  • 1. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes.
    Marcucci G; Silverman L; Eller M; Lintz L; Beach CL
    J Clin Pharmacol; 2005 May; 45(5):597-602. PubMed ID: 15831784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.
    Martin MG; Walgren RA; Procknow E; Uy GL; Stockerl-Goldstein K; Cashen AF; Westervelt P; Abboud CN; Kreisel F; Augustin K; Dipersio JF; Vij R
    Am J Hematol; 2009 Sep; 84(9):560-4. PubMed ID: 19650118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
    Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
    J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
    Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
    Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
    Garcia-Manero G; Gore SD; Cogle C; Ward R; Shi T; Macbeth KJ; Laille E; Giordano H; Sakoian S; Jabbour E; Kantarjian H; Skikne B
    J Clin Oncol; 2011 Jun; 29(18):2521-7. PubMed ID: 21576646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
    Musto P; Maurillo L; Spagnoli A; Gozzini A; Rivellini F; Lunghi M; Villani O; Aloe-Spiriti MA; Venditti A; Santini V;
    Cancer; 2010 Mar; 116(6):1485-94. PubMed ID: 20151429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.
    Wade M; Baker FJ; Roscigno R; DellaMaestra W; Hunt TL; Lai AA
    J Clin Pharmacol; 2004 Jan; 44(1):83-8. PubMed ID: 14681345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
    Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
    J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment.
    Laille E; Goel S; Mita AC; Gabrail NY; Kelly K; Liu L; Songer S; Beach CL
    Pharmacotherapy; 2014 May; 34(5):440-51. PubMed ID: 24877181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes.
    Uchida T; Ogawa Y; Kobayashi Y; Ishikawa T; Ohashi H; Hata T; Usui N; Taniwaki M; Ohnishi K; Akiyama H; Ozawa K; Ohyashiki K; Okamoto S; Tomita A; Nakao S; Tobinai K; Ogura M; Ando K; Hotta T
    Cancer Sci; 2011 Sep; 102(9):1680-6. PubMed ID: 21624006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
    Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
    Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration.
    Cárceles CM; Serrano JM; Marín P; Escudero E; Fernández-Varón E
    J Vet Med A Physiol Pathol Clin Med; 2006 Aug; 53(6):300-4. PubMed ID: 16901274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
    Fenaux P; Ades L
    Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes.
    Chou WC; Yeh SP; Hsiao LT; Lin SF; Chen YC; Chen TY; Laille E; Galettis A; Dong Q; Songer S; Beach CL
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e430-e439. PubMed ID: 28124500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs.
    Flory AB; Rassnick KM; Balkman CE; Kiselow MA; Autio K; Beaulieu BB; Lewis LD
    Am J Vet Res; 2008 Oct; 69(10):1316-22. PubMed ID: 18828689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.